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dYersinia pestis, the causative agent of plague, is an extremely virulent bacterium but there are no approved vaccines for protection against
t. Our goal was to produce a vaccine that would address: ease of delivery, mucosal efficacy, safety, rapid scalability, and cost. We developed
novel production and delivery system for a plague vaccine of a Y. pestis F1–V antigen fusion protein expressed in tomato. Immunogenicity
f the F1–V transgenic tomatoes was confirmed in mice that were primed subcutaneously with bacterially-produced F1–V and boosted orally
ith transgenic tomato fruit. Expression of the plague antigens in fruit allowed producing an oral vaccine candidate without protein purification
nd with minimal processing technology.
2005 Elsevier Ltd. All rights reserved.
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. Introduction
Plague is a disease caused by the bacteriumYersinia pestis.
t is transmitted between animals and humans by the bite of
nfected fleas or by direct contact or inhalation of infective
aterials. The most common form of the disease is bubonic
lague, which arises following a bite from a flea that has pre-
iously fed on an infected animal. Infection by Y. pestis in
he bubonic form results in swollen and tender lymph nodes
alled “bubos”, hence the name of the disease. Pneumonic
lague arises when there is a colonization of the alveolar
paces leading to pneumonia. This is the most feared form of
lague because of the rapidity with which the disease devel-
ps (1–3 days); the high mortality rate in infected individuals
almost 100%); and the rapid spread of the disease from per-
∗ Corresponding author. Tel.: +1 480 727 4430; fax: +1 480 727 8305.
E-mail address: lucrecia.alvarez@asu.edu (M.L. Alvarez).
son to person as a consequence of inhalation of aerosolized,
infected droplets [1].
Y. pestis is generally recognized to have caused three
major pandemics of disease in the 1st, 14th–17th and 19th
centuries, with 200 million deaths worldwide. In one of the
epidemics during the second plague pandemic, known as the
Black Death, it is estimated that over 30% of the popula-
tion of Europe died as a direct result of infection [1]. Today,
plague can be found predominantly in Southeast Asia, South-
west USA, Madagascar and other parts of Africa. Clearly, Y.
pestis still has the potential to cause large-scale outbreaks
of plague. Examples include an occurrence in India in 1994
and, most recently, in Congo in February 2005 [2]. These
outbreaks reminded the world that plague is still a potential
problem. Of greater concern is the possibility that Y. pestis
might be used as a bio-terrorism or biological warfare agent
because it has an alarming potential for causing massive mor-
bidity and mortality in an exposed population [3]. Pneumonic
264-410X/$ – see front matter © 2005 Elsevier Ltd. All rights reserved.
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plague is the most likely outcome in the illegitimate use of
Y. pestis as a weapon. Unfortunately, the last commercial
plague-vaccine, available in the US until 1999, offered poor
protection against pneumonic plague. It was a whole cell vac-
cine containing formaldehyde-killed Y. pestis strain 195/P
cells. The predominant protective immunogen present in this
vaccine was the F1-antigen and therefore, could not provide
protection against F1-negative strains of Y. pestis. In addi-
tion, it required a course of vaccination over six months and
carried a significant risk of transient, and severe, side effects
[4].
Antibiotic treatment of bubonic plague is usually effec-
tive but pneumonic plague is difficult to treat and death often
results even with antibiotic therapy. Therefore, to circumvent
a potential catastrophe after a natural or intentional outbreak
of Y. pestis, it is crucial to obtain an easy to deliver and eco-
nomic vaccine for the different forms of plague, particularly,
pneumonic plague.
Of all the Y. pestis antigens tested, only F1 and V induce
a good protective immune response against a challenge with
the bacterium [5]. The F1 (Fraction 1) antigen is the major
capsular protein. It forms a polymer composed of a protein
subunit and plays an important role in inhibiting phagocyto-
sis by macrophages [6]. The V antigen is a secreted protein
that regulates the translocation of the cytotoxic effector pro-
teins from the bacterium into the cytosol of mammalian cells
[
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response in mice. We intend to address key issues such as:
mucosal efficacy, ease of delivery, rapid scalability, safety,
and cost. The F1–V-antigen fusion protein was expressed in
transgenic tomato plants that were then molecularly charac-
terized. The F1–V transgenic tomato fruit were pooled and
freeze-dried to concentrate and standardize the dose of the
antigen. The immunogenicity of the oral plant-made vaccine
was tested in BALB/c mice which were primed subcuta-
neously (s.c.) using bacterially produced F1–V and boosted
orally with freeze-dried, powdered, F1–V transgenic tomato
fruit. The vaccine elicited IgG1 in serum and mucosal IgA in
fecal pellets.
2. Materials and methods
In the ELISAs and Western-blots described in this section,
the proteins used as standards for F1–V, F1, and V detection
were recombinant bacterial forms (named F1–V, rF1 or rV)
obtained as described by Heath et al. [10]. The primary anti-
bodies (anti-F1–V, anti-V, and anti-F1–V) and the antigens
used as standards were provided by A. Friedlander, USAM-
RIID, Ft. Detrick, MD.
2.1. F1–V design and insertion into different plant
expression cassettes
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f7]. The effector proteins (termed “Yops”) have a range of
unctions like promoting the death of phagocytic host cells
nd inhibiting the normal inflammatory response [8].
Protection afforded by candidate plague vaccines have
een significantly enhanced by combining the F1 and V pro-
eins [9,10]. Previous investigations have co-expressed the
1 and V proteins or an F1–V fusion protein [10–12]. Pro-
ucing the F1–V antigen fusion protein may be advantageous
o combining individual F1 and V antigens as purifying and
haracterizing one protein, rather than two, should lead to
ower manufacturing costs [10]. Also, an injected subunit
accine based on F1 and V antigens, using Alhydrogel as
n adjuvant, provides good protection against an airborne
hallenge with Y. pestis in mice [12–15]. Promising results
ere recently reported with a two-dose intramuscular F1 and
subunit vaccine in humans [16]. However, there is still a
lear need to provide alternative, economical vaccines more
uited to the large-scale immunization of populations. Such
vaccine would be ideally administered non-invasively and
romote a much better mucosal immunity against the infec-
ion. This is particularly desirable since aerosolization of
. pestis as a bio-weapon would deliver the pathogen to a
ucosal surface. The concept of a common mucosal immune
ystem predicts that induction of immunity at one mucosal
urface, such as the gut, can provide immunity at another
ucosal surface, such as the lung [17]. Thus, the potential
xists for oral delivery of Y. pestis’ antigens to elicit a pro-
ective immune response to plague.
We report production of an economical alternative
lague vaccine candidate and investigate its elicited immuneWe designed a synthetic gene encoding a fusion of the
. pestis F1 and V proteins [10] which was optimized for
xpression in dicotyledonous plants. The gene encoded the
ame amino acid sequence as found in the bacterial-derived
rotein but plant preferred codons were used and spurious
RNA processing signals were removed (Genebank acces-
ion # DQ229852). The gene was assembled by a commercial
upplier (Retrogen, San Diego, CA) and cloned into a com-
ercial PCR cloning vector, PCR Blunt 3.5 kb (Invitrogen,
arlsbad, CA), to give pTopoF1–V. The 1456 bp NcoI–SacI
ragment from pTopoF1–V was inserted into the plant expres-
ion vector pIBT210.1 [18] to make pF1–V-IBT210.1. The
xpression cassette contained the strong constitutive CaMV
5S promoter, tobacco etch virus 5′-UTR and the soybean
spB 3′ region. The expression cassette was purified from
F1–V-IBT210.1 after digestion with HindIII and EcoRI and
igated into pGPTV–BAR [19] to yield p35SF1–V (Fig. 1A).
GPTV–BAR, a binary vector for plant transformation, car-
ies the bar gene that confers resistance to the herbicide
ialaphos [20].
We obtained the Cassava Vein Mosaic Virus (CsVMV)
romoter (without a leader sequence) [21] on a proprietary
lasmid from Dow AgroSciences (Indianapolis, IN) and
ncorporated it into an expression cassette with the soybean
spB 3′ region [18]. The F1–V fusion gene was ligated into
his cassette using NcoI and SacI restriction sites and the cas-
ette was transferred into the binary vector pGPTV–Kan [19]
o make pCFV110 (Fig. 1A). The N-terminal signal peptide
rom the soybean vspA coding sequence [22] was inserted
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Fig. 1. (A) Structure of the T-DNA region of binary vectors used for transient expression of F1–V in N. benthamiana leaves. pCaSFV110 has the vspA signal
peptide (ER-targeted) and pCFV110 does not (cytoplasm targeted). In both binary vectors pCaSFV110 and pCFV110, F1–V is under the control of the Cassava
Vein Mosaic Virus (CsVMV) promoter. In 35S-F1V, transcription of F1–V is driven by the cauliflower mosaic virus 35S promoter (5′ CaMV 35S), and the
tobacco etch virus 5′ untranslated region (TEV-5′ UTR) mediates enhancement of translation initiation. The 3′ UTR and polyadenylation signal of soybean
vegetative storage protein gene (3′ vspB) lie 3′ of F1–V and mediates 3′ end processing of the transcript. Ag7: Agrobacterium gene 7 polyA signal. Analysis of
the F1–V fusion protein transient expression in N. benthamiana leaves by: (B) F1–V ELISA; and (C) anti-F1–V Western-blot. Lanes 1, 2 and 3: F1–V transient
expression driven by plasmids pCaSF1–V110, p35SF1–V and pCF1–V110, respectively. The total soluble protein (TSP) was extracted three and six days after
the agro-infiltration. Bars are the means ± S.E.M. values obtained for three different leaves. d.a.i: Days after infiltration; F1–V% TSP: F1–V percentage of total
soluble protein; P: 70 ng of purified bacterially produced F1–V.
into the NcoI site at the 5′ end of the F1–V gene to make
pCaSFV110 (Fig. 1A).
2.2. Transient expression of F1–V in Nicotiana
benthamiana leaves
The binary vectors p35SF1–V, pCF1–V110 and
pCaSF1–V110 were introduced separately into A. tume-
faciens strain LBA4404 [23] by electroporation. The
transformed bacterial strains were then used to infiltrate
N. benthamiana leaves. Bacteria were grown for 24 h at
28 ◦C, centrifuged at 6000 × g (AC 50.10 angle rotor,
Jouan CR3i), and the pellet resuspended in infiltration
buffer [10 mM 2-(N-morpholino)ethanesulfonic acid (MES),
pH 5.5, 300M acetosyringone] to an optical density at
600 nm of 0.5 using the SmartSpec 3000 spectrophotometer
(Bio-Rad, Hercules, CA). The Agrobacterium solution was
injected into fully expanded N. benthamiana leaves through
a small puncture using a 3 ml needle-less syringe. The leaf
tissue of the transfected area was collected on the third
and sixth day after the agroinfiltration. The tissues were
assayed immediately or frozen at −80 ◦C. This protocol was
modified from Huang and Mason [24].
2.3. Stable tomato transformation
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Briefly after, sterilization seeds were planted on half-
strength Murashige and Skoog (MS) medium (50 mg l−1
myo-inosytol, 2 mg l−1 thiamine HCl, 0.5 mg l−1 pyri-
doxine HCl, 0.5 mg l−1 nicotinic acid, 10 g l−1 sucrose
and 8 g l−1Difco bacto-agar, pH 5.8). Cotyledons were
excised before the first true leaves emerged and incubated
in the Agrobacterium suspension (optical density at 600 nm
of 0.5–0.6) for 10 min. Two strains of A. tumefaciens,
EHA105 [26] and LBA4404 [23], each containing the
binary plasmid 35SF1–V (Fig. 1A), were used for stable
transformation. After co-cultivation, cotyledon explants
were cultured with the adaxial sides up on selective 2Z
medium (4.3 g l−1 MS salts, 20 g l−1 sucrose, 100 mg l−1
myo-inosytol, 2 mg l−1 glycine, 10 mg l−1 nicotinic acid,
0.5 mg l−1 pyridoxine HCl, 0.5 mg l−1 Thiamine HCl,
0.5 mg l−1 folic acid, 0.5 mg l−1 d-biotin, 5.2 g l−1 agar,
300 mg l−1 timentin, 3 mg l−1 bialaphos, pH was adjusted
to 6.0). When shoots were approximately 2 cm tall, they
were transferred to selective rooting medium (4.3 g l−1 MS
salts, 30 g l−1 sucrose, 2 mg l−1 glycine, 10 mg l−1 nicotinic
acid, 0.5 mg l−1 pyridoxine HCl, 0.5 mg l−1 Thiamine HCl,
0.5 mg l−1 folic acid, 0.5 mg l−1 d-biotin, 8 g l−1 bacto-agar,
300 mg l−1 timentin, 2 mg l−1 bialaphos, pH was adjusted
to 6.0). Plants that rooted in selective rooting medium
containing bialaphos were selected for PCR and F1–V
ELISA analysis. Individual lines possessing the best F1–V
f
g
b
eAgrobacterium-mediated transformation of tomato
otyledons (Lycopersicon esculentum variety Tanksley
A234TM2R) was performed according to Walmsley et
l. [25] except that seeds were sterilized in 20% bleach
or 20 min and rinsed three times in sterile distilled water.ruit expression were self-pollinated and the resulting seeds
erminated on MS medium supplemented with 2 g l−1 of
ialaphos.
Subscript text used to describe a transgenic plant line, for
xample, T0 indicates the number of sexual cycles that have
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occurred after the transformation event. Hence, T0 is used to
identify the primary transgenic events (first generation) and
T1 are plants from the primary events (second generation).
2.4. Nucleic acids analysis
Fresh leaves from the tomato seedlings that regen-
erated on medium containing the herbicide bialaphos
were analyzed using REDExtract-N-Amp Plant PCR kit
(Sigma–Aldrich, Saint Louis, MO). Using primers specific
for TEV (5′-GCATTCTACTTCTATTGCAGC-3′) and VSP
(5′-GATACAGTCTCAGAAGACC-3′) sequences, an ampli-
con of 1.6 kb was expected in transgenic plants containing the
F1–V gene. The icycler thermo-cycler (Bio-Rad, Hercules,
CA) was programmed to run the PCR using an annealing
temperature of 55 ◦C and 35 cycles. A negative control of
wild type tomato genomic DNA and a positive control of
p35SF1–V plasmid were included in each experiment. PCR
samples were run on a 1% (w/v) agarose gel against a 1 kb
ladder (New England Biolabs, Ipswich, MA).
Genomic DNA was prepared from 1 g of young leaf tissue
using a CTAB extraction protocol [27]. Fifteen micrograms
of DNA was analyzed by Southern-blot hybridization accord-
ing to Sambrook et al. [28]. The DNA probe was made and
labeled by PCR using the 35SF1–V plasmid as a template
with the same primer set described above. Digoxigenin (DIG)
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RNA isolation Aid (Ambion, Austin, TX). The RNA samples
were quantified with the NanoDrop 1000 A Spectrophotome-
ter (Ambion, Austin, TX). Five micrograms of total RNA
was denatured with formaldehyde/formamide, separated on
a 1% (w/v) agarose MOPS-acetate-EDTA gel, and stained
with SYBR safe (Invitrogen, Carlsbad, CA). Afterwards,
the RNA was transferred to a Zeta Probe membrane (Bio-
Rad, Hercules, CA), by capillary action, as described by
Sambrook et al. [28], and fixed by UV cross-linkage. The
membrane hybridization, washes, and detection were done
as with Southern analysis.
2.5. Protein extraction from leaves and freeze-dried fruit
Between 50 and 100 mg of young leaf or freeze-dried
tomato powder was collected in 2 ml micro-centrifuge tubes
for fast-prep (Fisher Scientific, Pittsburgh, PA). The tis-
sue was treated with liquid nitrogen and pulverized using
a micro-spatula. The powder was resuspended in 3 ml of
PBS extraction buffer (phosphate-buffered saline, pH 7.2
and 10g ml−1 leupeptin) per gram of leaf, or in 8 ml fruit
extraction buffer (50 mM sodium phosphate, pH 6.6; 100 mM
NaCl; 1 mM EDTA; 10g ml−1 leupeptin) per gram of fruit
powder. One bead (1/4 in. ceramic spheres beads; Qbiogene,
Carlasbad, CA) was added to each tube before homogeniza-
tion in a fast-prep machine (Fast-prep FP120 Bio, QBiogene,
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iabeled dUTP was incorporated into the 1.6 kb amplicon
ccording to the manufacturer’s instructions (PCR DIG probe
ynthesis kit, Roche Applied Science, Indianapolis, IN).
The reconstruction of the gene copy number was done
sing 39.5 pg, 197.5 pg and 395 pg of the 35S-F1V plas-
id digested with HindIII and EcoRI (amounts equivalent
o 1, 5 and 10 copies of F1–V gene per tomato haploid
enome, respectively). Those amounts were calculated tak-
ng into account the size of the tomato haploid genome
655,000,000 bp) and the amount of plant genomic DNA used
n this assay (9g). The F1–V gene copy number was deter-
ined for each T1 tomato plant using densitometric analysis
nd comparing the intensities of each band in the Southern-
lot with those corresponding to 1, 5 and 10 copies.
Hybridization was done for 18 h at 45 ◦C using the Dig
ast Hyb solution (Roche Applied Science, Indianapolis,
N) and 5l ml−1 Dig PCR-labeled F1–V probe. The mem-
rane was first washed three times, 10 min each, with low
tringency buffer (0.30 M sodium chloride, 0.030 M sodium
itrate, 0.1% (w/v) SDS) at room temperature. Afterwards,
he membrane was washed twice, 30 min each, with high
tringency buffer (0.03 M sodium chloride, 0.003 M sodium
itrate, 0.1% (w/v) SDS). The detection was done as per the
anufacturer’s instructions (DIG block and wash buffer set
nd DIG Luminescent Detection Kit, Roche Applied Science,
ndianapolis, IN). Southern analysis of the plant lines was
isualized after exposing the membrane to KODAK BioMax
S film.
Total RNA samples were isolated from 500 mg of young
eaf tissue using RNAqueous (Ambion, Austin, TX) and Plantarlasbad, CA) for 15 s at speed 4. The tubes were then cen-
rifuged at 20,800 × g (Eppendorf microcentrifuge 5417R)
or 5 min and the supernatant transferred to a new 1.5 ml
ube. The total soluble protein concentration of the extracts
as determined by Bradford Assay [29] (Bio-Rad, Hercules,
A), using known concentrations of bovine serum albumin
BSA) as the protein standard.
.6. Western-blot analysis to detect F1–V fusion protein
n transgenic plants
Five micrograms of total soluble protein (TSP) per sam-
le was added to 6l 6 × SDS gel loading buffer (300 mM
ris–HCl, pH 6.8, 600 mM dithiothreitol, 12% SDS, 0.6%
romophenol Blue, 60% glycerol), boiled for 10 min and
laced on ice. Bacterially produced F1–V fusion protein
as used as a positive control. The samples were cen-
rifuged at 20,800 × g (Eppendorf 5417R microcentrifuge)
or 5 min at 4 ◦C and then loaded on a SDS-polyacrylamide
el (10.5–14% Tris–HCl, 4% stacking, Bio-Rad, Hercules,
A). The gel was run at 30 mA for 3 h using Tris–glycine
unning buffer (25 mM Tris, 250 mM glycine, pH 8.3, 0.1%
DS). The separated proteins were transferred from the gel
o a PVDF membrane (Bio-Rad, Hercules, CA) using a Mini-
rans-Blot electrophoretic transfer cell (Bio-Rad, Hercules,
A) and run left overnight at 17 V (Bio-Rad, Hercules, CA).
he membrane was then blocked with 2.5% dry milk in PBST
or Western (PBS buffer plus 0.1% Tween 20) for 2 h at room
emperature. After a brief wash in PBST, the membrane was
ncubated with rabbit polyclonal antibody against F1–V, at
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dilution 1:2000 in 1% dry milk in PBST, for 1 h at 37 ◦C. After
a 15 min wash followed by three 5 min washes, the mem-
brane was incubated with horseradish peroxidase conjugated
goat polyclonal IgG antibody against rabbit (Sigma–Aldrich,
Saint Louis, MO), diluted at 1:10000 in 1% dry milk in PBST.
The membrane was then washed in PBST for 15 min followed
by three washes of 5 min. Protein detection was performed
using ECL Plus (Amersham Biosciences, Piscataway, NJ)
according to the manufacturer’s instructions.
2.7. Enzyme-linked immunosorbant assay analysis
(ELISA)
The total soluble protein (TSP) was extracted from freeze-
dried fruit and fresh leaves as previously described. The
extracts were incubated in the ELISA plate (high bind
polystyrene EIA/RIA 96 well microplate, Corning, NY) for
2 h at 37 ◦C, followed by three washes with PBST for ELISA
(PBS plus 0.05% Tween 20), and blocking with 5% (w/v)
dry milk in PBST for 1 h at 37 ◦C. After another three
washes, rabbit anti-F1–V polyclonal antibody (or anti-V or
anti-F1 polyclonal antibody for V- or F1-ELISA, respec-
tively) at a dilution of 1:4000, was added and incubated
for 2 h at 37 ◦C. After another three washes with PBST, the
plate was incubated with peroxidase labeled goat anti-rabbit
(Sigma–Aldrich, Saint Louis, MO) at a dilution of 1:3000 in
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one-half cup of mixed nuts (peanuts, cashews, almonds, hal-
berts, brazils), two tablespoons of honey, and one-fourth cup
of water. The pH of the food mix was adjusted to 7. Five of the
11 mice were fed with control tomato powder and the other six
with transgenic tomato powder containing 300g of F1–V on
days 21, 28 and 35 and a final higher dose of 1200g on day
42. In the first three boostings only tomatoes from T0 plants
were used. On the fourth and last boost, green tomatoes from
the T1 plants were used increasing the dosage by four-fold.
On the day of the boosting, mice were removed from their
cages to individual holding cages with water and fasted for
18 h. Before delivery of the orally administered transgenic or
non-transgenic tomato material, 10g of purified bacterial
cholera toxin (Sigma–Aldrich, Saint Louis, MO) was given
to the mice as an adjuvant in 0.25 ml sodium carbonate buffer
(350 mM), pH 8.5 by gastric intubation (gavage) [30]. Resid-
ual test diet, if any, was collected and weighed to determine
the amount ingested by the animals. All the animals were
housed separately so that fecal pellets could be collected.
Samples of fecal pellets and serum (100l by way of tail
bleed using a 22 G needle) were collected on days −1, 20,
27, 34 and 41 to determine anti-F1 and anti-V IgG or IgA
antibody by ELISA. Animals were provided with food and
fresh water ad libitum during the experiment except for the
days of boosting when they were only provided with water
and the test diet. The experimental protocol involving mice
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fBST and final detection performed using TMB peroxidase
ubstrate (Bio-Rad, Hercules, CA). The reaction was stopped
fter 5 min with 1 N H2SO4 and the optical density was read
t 450 nm using the Microplate Reader Thermo Max (Molec-
lar Devices Inc., Sunnyvale, CA).
.8. Tomato fruit processing
A fresh fruit sample from each T0 and T1 tomato plant
ere collected, kept overnight at −20 ◦C and then freeze-
ried (100 SRC Virtis freeze-drier) for at least 72 h. The dried
ruit coming from the same plant was then pulverized to a
owder, pooled and stored in vacuum-sealed plastic bags at
oom temperature.
.9. Animal trials: prime-boost strategy
Female BALB/c mice, six–eight weeks old, raised under
pecific-pathogen-free conditions (Charles River Laborato-
ies), were used in this study. The mice were divided into
roups of five or six for immunization using a prime-boost
trategy. On day 0, 11 mice received a sub-cutaneous (s.c.)
rime of 10g purified, bacterially produced F1–V fusion
rotein adsorbed to the aluminum hydroxide adjuvant, Alhy-
rogel (AL), at 0.19 mg per dose (Heath et al., 1998 [10]),
uspended in a volume of 0.2 ml MilliQ ultrapure (Millipore,
illerica, MA) sterile water. The test diet in the feed treat-
ents consisted of 2 g of freeze-dried tomato fruit powder
lended with 7 g of food mixed with a blender comprised
f: two whole apples (small Washington Delicious apples),as approved by the Arizona State University Animal Care
nd Use Committee.
.10. Determination of IgG1 and IgG2 titers in serum
nd IgA titers in fecal samples
ELISA plates (high bind polystyrene EIA/RIA 96-well
icroplate, Corning, NY) were coated with 2.5g ml−1 rF1
r rV antigen in PBS and incubated overnight at 4 ◦C. After
hree washes with PBST for ELISA (PBS, pH 7.4, plus 0.05%
ween 20), plates were blocked with 1:10 dilution of fetal calf
erum (FCS) in PBS and incubated for 1 h at 37 ◦C. After
hree washes with PBST, the serum was serially diluted two-
old in the plates using FCS and starting at 1:100. The plates
ere then incubated for 1 h at 37 ◦C before being washed
hree times with PBST and incubated with horseradish per-
xidase (HRP) conjugated goat anti-mouse-IgG1 (Southern
iotech), at a dilution of 1:4000 in blocking buffer (1:10 dilu-
ion FCS in PBS), for 1 h at 37 ◦C. For IgG2a, the plates were
ncubated with HRP conjugated goat anti-mouse-IgG2 anti-
ody (Southern Biotech), at a dilution of 1:4000 in blocking
uffer, for 1 h at 37 ◦C. After washing four times with PBST,
he detection was done using TMB peroxidase substrate (Bio-
ad, Hercules, CA) for 5 min. The reaction was stopped with
N H2SO4 and then the absorbance read at 450 nm using the
icroplate Reader Thermo Max (Molecular Devices Inc.,
unnyvale, CA). Titers were estimated as the reciprocal of
he maximum dilution of serum giving an absorbance reading
f 0.1 units after subtraction of non-specific binding in serum
rom non-treated animals (negative control). Concentrations
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of serum anti-F1 or anti-V IgG1 or IgG2a were determined
by linear regression from a standard curve of mouse myeloma
IgG1 or IgG2a (Sigma–Aldrich, Saint Louis, MO).
Fecal samples were prepared by adding 5 ml of extrac-
tion buffer (PBS, 0.1% Tween 20 and 10g ml−1 leupeptin)
per gram of material. Suspensions were kept for 30 min at
4 ◦C and thoroughly homogenized with a QBiogene Fast Prep
machine for 1 min. After incubating for another 30 min at
4 ◦C, suspensions were centrifuged for 10 min at 20,800 × g
(Eppendorf microcentrifuge 5417R), at 4 ◦C. The super-
natant was collected and clarified again by centrifuging at
20,800 × g at 4 ◦C for 1 min. The twice-clarified supernatant
was collected and stored at −20 ◦C until it was assayed
or immediately analyzed by ELISA. The total soluble pro-
tein (TSP) in each sample was tested using the Bradford
Assay (Bio-Rad, Hercules, CA). Two-fold serially diluted
samples, starting at 50g of TSP, were applied onto the
plates (previously coated with rF1 or rV and blocked as
was already described for serum samples) and incubated for
1 h at 37 ◦C. After washing three times with PBST, plates
were incubated for 1 h at 37 ◦C with anti-mouse-IgA anti-
body (Sigma–Aldrich, Saint Louis, MO) diluted 1:1000 in
blocking buffer. Detection was performed as was previously
described for serum samples.
2.11. Statistical analysis
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exact test was applied to determine significant differences in
the number of transgenic plants obtained using A. tumefa-
ciens strain LBA4404 or EHA105.
3. Results
3.1. Transient expression of F1–V in N. benthamiana
leaves
We studied and compared the F1–V transient expression
in N. benthamiana leaves using three different plasmid
constructions: p35SF1–V, pCF1V110 and pCaSF1V110
(Fig. 1A). N. benthamiana leaves were infiltrated with three
different cultures of A. tumefaciens strain LBA4404 bearing
one of the three different plasmid constructs. The soluble pro-
teins extracted three and six days after agroinfiltration were
analyzed by ELISA (Fig. 1B) and Western-blot (Fig. 1C).
The transient F1–V expression using plasmid p35SF1–V
is significantly higher (P= 0.006) than that obtained using
plasmids pCaSF1–V110 or pCF1–V110. Both constructs
use the CsVMV promoter to drive expression of F1–V.
However, pCaSF1–V110 contains sequences coding for
the soybean vegetative storage protein signal peptide vspA
(VSP alpha S) fused to F1–V, which is expected to target
F1–V to the endoplasmic reticulum (ER). pCF1–V110
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AAll statistical analyses were performed using the soft-
are SPSS 13.0 for Windows. Regardless of the test applied,
esults were considered statistically significant if P< 0.05. A
epeated measure ANOVA with a Turkey-Kramer multiple
omparisons test was used to determine significant differ-
nce between detected F1–V, F1 and V in the same protein
xtract. The same test was applied to determine significant
ifference between F1–V percentage of total soluble pro-
ein (F1–V% TSP) of fresh leaves, green and red powdered
omato. The one-way ANOVA test, with a post hoc Dunnett
3 test, was used to determine significant differences in F1–V
ercentages of total soluble protein (F1–V% TSP) between
ifferent tomato ripening fruit stages. The same test was used
o compare F1–V transient expression in N. benthamiana
eaves using three different plasmid constructs (pCF1–V110,
CaSF1–V110 or 35SF1–V). A two-tailed paired Student’s t-
est was applied to determine significant differences in serum
1- and V-specific IgG1 and IgG2a before and after boost-
ng with control or F1–V transgenic tomatoes (intra-groups
omparison). The Levene’s test was applied to determine
quality of variances in the antibody concentrations between
he mice group boosted with control tomatoes or the group
oosted with F1–V transgenic tomatoes (inter-groups com-
arisons). When the variances were equal (p> 0.05), the
npaired Student’s t-test for equality of the means was applied
o determine significant differences in pre-boost or post-boost
ntibody concentrations. When the variances were unequal
p< 0.05 in Levene’s test), an unpaired Student’s t-test with
elch corrections for different variances was used. Fisher’soes not contain this sequence, hence expression should
e targeted to the cytoplasm. Transient F1–V expression
sing pCF1–V110 is significantly higher (P= 0.007) than
hat found with pCaSF1–V110. Transient, F1–V expression
s significantly higher (P< 0.05) at 3 days after infiltration
d.a.i.) than at 6 d.a.i. (Fig. 1B) with all three constructs.
LISA analysis of Agrobacterium cultures containing the
1–V constructs verified that there was no expression of the
usion protein by the bacteria (data not shown) and, therefore,
he expression observed in leaves was derived only from
eaf cells.
A specific band of 53 kDa corresponding to the F1–V
usion protein was detected by Western-blot in the positive
ontrol (lane “P”, bacterially produced F1–V) and in all the
ample lanes, except for the W.T. (wild type) control lane
Fig. 1C).
The plasmid p35SF1–V was used for stable transforma-
ion of tomato on the basis of the higher levels of transient
xpression.
.2. Screening of transgenic plants
We used two differentA. tumefaciens strains, EHA105 and
BA4404, in stable tomato transformation experiments. Out
f 175 explants (cotyledons) transformed with the p35SF1–V
ector carried by Agrobacterium strain LBA4404, 58 tomato
lants resistant to the herbicide bialaphos were regenerated
nd 29 (50%) of them were positive for the F1–V gene by
CR. The same number of explants were transformed with
grobacterium strain EHA105 resulting in 61 tomato plants
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being selected using bialaphos. Of these, 37 (61%) were
positive for the F1–V gene by PCR. Regardless of the strain
used for transformation, there is no significant difference
(P= 0.27) in the number of F1–V or bialaphos transgenic
tomato plants obtained. However, use of EHA105 resulted
in more rapid plant regeneration.
A total of 66 out of 119 plants regenerated on Bialaphos
selective medium were positive by PCR for F1–V. In addi-
tion to the specific F1–V amplification product of 1.6 kb,
there was a spurious band of about 600 bp that was always
present even in the W.T. negative control (Fig. 2). The inten-
sity of this non-specific extra band was proportional to the
amount of DNA template in all cases. Therefore, we were
able to use it as a positive internal control for the PCR
reaction.
3.3. F1–V fusion protein expression in T0 and T1 tomato
plants
Fresh leaves of the 66 T0 tomato plants found positive
by PCR were analyzed by Indirect F1–V ELISA. Five T0
plants (transformants 4, 8, 21, 22 and 23) were considered and
were carried forward because of their higher F1–V expres-
sion. Tomato fruit from the same plants expressing the fusion
protein F1–V were pooled and freeze-dried to increase their
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Fig. 3. F1–V fusion protein expression in pooled, fresh leaves, green and red
freeze-dried tomato fruit from: (A) T0 lines and (B) T1 lines. F1–V% TSP:
F1–V percentage of total soluble protein. The name of each T1 plant begins
with the parent T0 plant before the dot and the specific T1 plant number after
the dot. Bars are means of three repetitions ± S.E.M.
green fruit for plant 4.14. However, all the other T1 lines had
significantly higher percentages of TSP in green freeze-dried
fruit than in fresh leaves (P< 0.05) and red freeze-dried fruit
(P< 0.01). In all the cases, the T1 tomato plants showing high
antigen expression in fruit or leaves had indistinguishable
phenotypes from non-transgenic control plants or plants with
low antigen expression levels.
There are six tomato fruit ripening stages according to
the California Tomato Commission: green, breakers, turn-
ing, pink, light red, and red (http://www.tomato.org/reflex/
food/color.html). We analyzed pooled, freeze-dried tomato
fruit at each stage, from the same T1 plant, T23.13, by F1–V
ELISA (Fig. 4A). We found that the F1–V percent of TSP in
pooled fruit at ripening stage 1 (fruit fully developed but still
completely green) is significantly higher than in all the other
stages (P< 0.01 in all cases). Similar results were found with
all other T1 lines (data not shown), therefore, we used only
green fruit for vaccine powder production from T1 generation
plants for the final boosting. Red tomato fruit were collected
only for seed harvest.
Western-blot analysis was used to investigate the integrity
of the F1–V fusion protein in green, pooled, freeze-dried
tomato fruit from six of the T1 lines. A strong band of 53 kDa
corresponding to the F1–V fusion protein was present in all
the sample lanes except in the W.T. (wild type or negativehelf-life. Fig. 3 shows the comparison of the F1–V expres-
ion in fresh leaves with red and green freeze-dried tomatoes
n different T0 and T1 plants.
We chose a total of nine T1 plants (4.6, 4.12, 4.14, 4.48,
.51, 4.52, 22.1, 23.7, 23.13) because of their high F1–V
xpression levels in leaves and fruit (Fig. 3B). Expression of
1–V varied from 0.9 to 4.6% TSP in fresh leaves. There
s no significant difference between the percent of TSP in
oth green and red fruit for plant 4.6 or between leaves and
ig. 2. PCR analysis of genomic DNA extracts from T0 tomato plants. MM:
olecular marker 1 kb ladder. Band sizes are in kb. W.T.: wild type (non-
ransformed tomato). H2O: amplification without plant DNA using water as
he template. P: positive control (amplification product from p35SF1V). The
rrow points out the specific F1–V amplification product (1.6 kb).
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Fig. 4. Expression of F1–V fusion protein in pooled, freeze-dried fruit. (A)
F1–V% TSP in six different fruit ripening stages, from the T1 line 23.13.
(B) Western-blot for F1–V in pooled, green, freeze-dried tomato fruit from
six different T1 lines. All samples were standardized to contain 5g of total
soluble protein (TSP). F1V% TSP: F1–V percentage of total soluble protein.
W.T: wild type (non-transformed plant). Bars are the means of three repe-
titions ± S.E.M. P: positive control (10 ng of purified bacterial recombinant
F1–V).
control) (Fig. 4B). The lower molecular weight bands may
correspond to minimal partial degradation products of the
mature protein.
The antigenicity of the plant-made F1–V fusion protein
and each of its individual components (F1 and V), was stud-
ied using F1, V and F1–V ELISA of the same protein extracts
from three T1 lines (Fig. 5). The amount of F1–V per gram of
dried fruit determined by F1–V ELISA is significantly higher
than F1 or V antigen alone in the three T1 plants analyzed
(P< 0.05 in all the cases). However, there is no significant
difference between F1 or V antigen levels in the three plants
studied. The F1-antibody recognizes the plant-derived F1–V
(54 kDa. band, lane 4.51, Fig. 6A); the recombinant bacte-
rially expressed F1–V and F1, but not V (F1-Western-blot,
Fig. 6A). The V-antibody recognizes the plant-derived F1–V
(54 kDa band); the recombinant bacterially expressed F1–V
and V, but not F1 (V-Western-blot, Fig. 6B).
3.4. Nucleic acid analysis of T1 tomato plants
It is well known that transgene copy number can affect
the level and stability of transgene expression, determining
Fig. 5. Comparison of F1, V and F1–V antigen detection by F1, V and F1–V
ELISAs in the same protein extracts from green freeze-dried fruits of T1
plants 4.51, 22.11 and 23.7. In each case the standard curve was constructed
using bacterial F1, V and F1–V, respectively. DW: dry-weight. Bars are
means of three repetitions ± S.E.M.
Fig. 6. Antigenicity study of the F1–V fusion protein in green, freeze-dried
fruit. (A) F1-Western-blot using F1-specific antibody. (B) V-Western-blot
using V-specific antibody. Lanes 4.51 and W.T.: protein extracts from green
freeze-dried fruit from T1 plant 4.51 and wild type, respectively.
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in most of the cases the susceptibility of the gene to silencing
[31,32]. Hence, the F1–V transgene copy number of the T1
tomato plants was estimated by Southern-blot analysis. An
expected specific band of about 2800 bp, corresponding to
the 35S-F1V cassette digested with EcoRI and HindIII, was
present in all the lines except in the W.T. (wild type or non-
transformed tomato plant) (Fig. 7A). An accurate calculation
of gene copy number in sibling plants 23.7 and 23.13 was
confounded because of bands with higher molecular weights
in addition to the expected size of 2.8 kb. These bands likely
correspond to different F1–V insertion sites where at least
one of the restriction sites at the border of the 35SF1–V
cassette, for HindIII or EcoRI, has disappeared by mutation
or deletion. The same could have happened with the 4.8 kb
extra band in lanes 1, 2 and 3 (plants 4.12, 4.14 and 4.51,
all siblings coming from plant T4). Table 1 summarizes the
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Table 1
F1–V gene copy number, and fusion protein expression in green freeze-dried
pooled tomato fruit
T1 plant g F1–V g−1 DWa
(green fruit)b
F1–V gene copy
numberc
4.12 1669 ± 184 5
4.14 860 ± 23 4
4.51 880 ± 50 6
22.11 1660 ± 134 2
23.7 1694 ± 60 About 15 copies
23.13 1392 ± 134 About 9 copies
a DW: dry-weight.
b Values are means ± S.E.M. (three repetitions per plant).
c Estimated by Southern-blot.
estimated F1–V gene copy number in each T1 plant. There
is a weak positive correlation between the F1–V gene copy
number and the F1–V protein levels in green, freeze-dried
tomatoes in the T1 plants (Pearson’s correlation r= 0.2848).
Only 8% of the variance in the F1–V protein levels in green
fruit can be explained by variation in F1–V gene copy number
(coefficient of determination r2 = 0.08).
Northern-blot analysis of total RNA extracted from leaves
of T1 plants revealed a band of approximately the predicted
size (2.1 kb) in all the experimental plants but not in the W.T.
lane (Fig. 7B). In spite of the fact that the same amount of
total RNA was loaded per sample (Fig. 7C) and the plants
have different F1–V gene copy numbers (Fig. 7A), the F1–V
mRNA band intensity was similar for all the transgenic plants
(Fig. 7B).
3.5. Oral immunogenicity of dried F1–V tomato in mice
The ability of F1–V in freeze-dried tomato fruit to induce
serum and mucosal antibodies when fed to BALB/c mice was
tested in prime-boost experiments. F1- and V-specific serum
immunoglobulin G1 (IgG1) was detected in 100% of the mice
that were primed subcutaneously with bacterial F1–V and
boosted with control or F1–V transgenic tomato. The peak
of the serum F1- and V-specific IgG1 occurred at 21 days
a
tig. 7. Nucleic acid analyses of T1 tomato plants. (A) Southern-blot of
enomic DNA digested with EcoRI and HindIII that cut at both extremes
f the 35S-F1V cassette. A DIG-labeled F1–V probe was used to detect the
ene. 1c; 5c; and 10 c: 1, 5 and 10 copies of 35S-F1V, respectively. W.T: wild
ype. Numbers above each band represent the estimated gene copy number
etermined by densitometric analysis of the intensity of each band compared
o 1, 5 and 10 copies of the 35S-F1V (for total F1–V gene copy number per
lant see Table 1). White arrows point out extra high molecular weight bands
additional to 2.8 kb) corresponding to more gene insertion sites. (B) Total
NA (5g) from wild type (W.T.) and transformed T1 tomato plants was
eparated on a 1% (w/v) formaldehyde agarose gel followed by capillary
ransfer and hybridization with F1–V probe labeled with digoxigenin. (C)
RNA quality in SYBR stained 1% (w/v) agarose gel. Lanes 1–7 correspond
o the following T1 plants: 4.12; 4.14; 4.51; 4.52; 22.11; 23.7 and 23.13,
espectively.
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ifter the last boost (a.l.b.) at day 63 post-primary immuniza-
ion. Fig. 8 shows the analysis by ELISA of serum and fecal
ellets at 21 days after the last boost. The average of serum
1- and V-specific IgG1 (n= 6) is significantly higher after
he mice were boosted with F1–V tomatoes (P= 0.030 and
= 0.023, respectively) (Fig. 8A and B, respectively). In the
ontrol group of mice (n= 5), there is no significant increase
n serum F1-specific (P= 0.79) or V-specific (P= 0.08) IgG1
fter boosting with control tomato powder. However, the F1-
nd V-specific IgG1 are significantly higher (P= 0.04 and
.03, respectively) in mice boosted with transgenic F1–V
omatoes than in the mice boosted with control tomato fruit
Fig. 8A and B, respectively).
F1- and V-specific serum immunoglobulin G2a (IgG2a)
as detected in 100% of the mice immunized with subcuta-
eous bacterial F1–V in sera collected on day 21 a.l.b. There
s a significant difference in the average serum F1-specific
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Fig. 8. Prime-boost experiments in BALB/c mice. Prime: subcutaneous F1–V; Boost: W.T. (wild type) or F1–V tomato. (A) Average serum F1-specific IgG1
(n= 6); (B) average serum V-specific IgG1 (n= 6); (C) average serum F1-specific IgG2a; (D) average serum V-specific IgG2a. Bars represent the group mean
endpoint concentrations in (g ml−1). Error bars are ±S.E.M. Mucosal IgA in fecal pellets per mouse: (E) F1-specific mucosal IgA; (F) V-specific mucosal
IgA.
IgG2a (P= 0.012) after mice (n= 6) were boosted with
transgenic tomato (Fig. 8C). However, the difference in the
average serum V-specific IgG2a after boosting with F1–V
transgenic tomatoes is not significant (P= 0.18) (Fig. 8D),
and neither is the difference in F1- and V-specific IgG2a in
mice boosted with control tomatoes (n= 5).
F1-specific and V-specific mucosal IgA was detected in
fecal pellets in two out of six mice 21 days after the last
boosting with transgenic F1–V tomato (Fig. 8E and F). Par-
ticularly, mouse number 6 (M6) had an eight-fold increase in
the F1-specific sIgA and a six-fold increase in the V-specific
sIgA in fecal pellets after the last boost with the transgenic
tomato fruit. In mice immunized only subcutaneously with
bacterially produced F1–V or in those boosted with control
tomato, F1- or V-specific sIgA was not detected at any time
during the assay (an OD at 450 nm lower than 0.1 was con-
sidered background).
4. Discussion
There have been previous initiatives to devise an alterna-
tive plague vaccine that could be administered needle-free
and they are currently being tested in animal trials by dif-
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ferent research groups. One of these is a micro-encapsulated
preparation of F1 and V antigens, delivered intranasally to
mice, that protects against parenteral and inhalation chal-
lenges with Y. pestis [33]. Another utilizes oral immunization
with a recombinant Salmonella enterica expressing Y. pestis’
antigens that has also been reported to provide protection
against a subsequent challenge with the bacteria [34–36].
The production of therapeutic proteins in plants represents
an economical alternative to fermentation-based expression
systems, especially for the manufacturing of high-volume
reserves of subunit vaccines (for a review see [37]). Plants
have been shown to provide both an encapsulated antigen
and an oral delivery system. Plant-made vaccine antigens
can be delivered to a mucosal surface (for example, when
provided orally or intranasally). Additionally, plants can be
grown locally and inexpensively using the standard growing
methods of a given region and can also be produced virtually
indefinitely from seeds [38]. Oral delivery is made possible
because it is believed that the plant cell wall provides enough
protection against degradation to allow much of the vaccine
antigen expressed in the cells to reach the gut-associated lym-
phoid tissue (GALT) in an intact and immunogenic state.
Since plant-made vaccines were first described by Curtis
and Cardineau [39], different groups have experimented with
transgenic plants for expression and oral delivery of recom-
binant vaccine antigens. The six human clinical trials accom-
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lum targeted in the transient assay; and (d) the F1–V transient
expression using any of the three plasmid constructs is sig-
nificantly higher at 3 d.a.i. than at 6 d.a.i.
Of 66 primary transformants positive for F1–V by PCR,
only five plants were selected as lines, based on F1–V
expression analyses, and advanced to the T1 second gen-
eration. We selected nine second generation tomato plants
expressing high concentrations of the fusion protein F1–V
in fruit (4–10% of TSP, 600–1700g g−1 of green freeze-
dried tomato fruit). We analyzed the antigenicity of the F1–V
fusion protein in extracts from pooled, freeze-dried tomato
fruit. There is a significant difference (P< 0.05) in the F1–V
amount detected by F1–V ELISA compared to the F1 and
V amounts detected by F1 and V ELISA, respectively, in
the same protein extract (Fig. 5). This fact could be a conse-
quence of a lower antigenicity of the F1 and V proteins when
they are part of the plant-made fusion protein as opposed to
separated bacteria-made proteins. However, the antigenicity
of F1 and V in the plant-derived F1–V fusion protein was
sufficient to be recognized by the antibodies specific for the
bacterial F1 and V (Fig. 6A and B, respectively), as well as
to induce an immune response in mice (Fig. 8).
It is generally accepted that the murine model of plague
is able to provide a meaningful indication of the efficacy of
plague vaccines. This model has previously been approved
by the US Public Health Service for the testing of plague
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tlished with plant-made vaccines have shown the potential
f using the plant-made vaccine technology [40–45].
In this paper, we describe the development and evalua-
ion of an alternative oral subunit vaccine candidate against
lague, produced by expressing the F1–V fusion protein in
omato. To our knowledge, this is the first report of a plant
ade, orally delivered plague-vaccine. Tomato has many
dvantages over other host plants for the production of oral
accines. Tomato yields large masses of palatable fruit that
re edible raw (avoiding heat denaturation of the antigens)
nd has well established industrial greenhouse culture and
ruit processing. Unfortunately, a vaccine expressed in fresh
omato fruit has a short shelf-life. For this reason, fresh tomato
ruits expressing the fusion protein F1–V were pooled and
reeze-dried. Freeze-drying is a well-established technology
hat is inexpensive and provides antigen stability at room tem-
eratures, batch consistency and concentrated antigen. The
ntegrity and antigenicity of the F1–V fusion protein in the
reeze-dried, tomato fruit powder was confirmed by ELISA
nd Western-blot analyses.
We constructed three different plasmid binary vectors
earing the F1–V fusion protein: p35SF1–V, pCaSF1–V110
nd pCF1–V110 (Fig. 1A). Transient expression of these vec-
ors found: (a) the plant-made F1–V fusion protein retained
ts native antigenicity since it was recognized by polyclonal
ntibody targeted against the bacterially produced F1–V; (b)
aMV35S promoter/TEV-5′ UTR is significantly better than
sVMV promoter at driving high expression of F1–V in
he transient assay; (c) the F1–V expression is significantly
igher when it is cytoplasm rather than endoplasmic reticu-accines [46]. Glynn et al. [47] demonstrated that alternating
outes for delivery of the priming and booster doses (known
s prime-boost strategy) in immunizations with F1–V fusion
rotein, can be as or more effective than homologous boosting
or induction of serum anti-F1–V IgG1 responses. We used
ALB/c mice that were previously primed with parenteral
1–V to test the immunogenicity of the orally administered
1–V transgenic tomatoes. In the first three boosts, we used
g of freeze-dried transgenic tomatoes (300 ug of F1–V)
erived from the first generation (T0) of transgenic plants.
he fourth and final boost also consisted of 2 g of freeze-
ried transgenic tomatoes but was derived from the second
eneration plants (T1) that have at least a four-fold increase
n F1–V expression in the fruits as compared to the first gen-
ration. For this reason, the final dose was increased from
00 ug to 1200g.
The F1- and V-specific IgG1 concentrations were signif-
cantly higher in mice boosted with the transgenic tomato
ruit than in mice boosted with W.T. (non-transgenic tomato
ruit). Williamson et al. [48] found that the combined titers of
he IgG1 subclass, developed to F1 plus V, correlates signif-
cantly (P< 0.05) with protection against a challenge with Y.
estis s.c. at 107 CFU in BALB/c mice. Based on this study,
e estimated the possible degree of protection in the mice
nder the prime-boost experiments with control or F1–V
ransgenic tomato fruit (Table 2). The average predicted per-
entage of protection for those values of log10 IgG1 titers
o (F1 + V) is 50–90% for the mice boosted with transgenic
omato fruit but only 10% for the five mice boosted with con-
rol tomato. When the log10 F1 + V IgG1 was calculated per
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Table 2
Predicted protection against challenge with Y. pestis s.c. at 107 CFU in BALB/c mice primed with s.c. bacterially produced F1–V and boosted with control or
F1–V transgenic tomato fruit
IgG1 specificity Avg. log10 F1 + V IgG1 titer after
boosting with TG F1–V tom. (n= 6)a
Predicted % of
protectionb
Avg. log10 F1 + V IgG1 titer after
boosting with W.T. tom. (n= 5)a
Predicted % of
protectionb
F1 5.21 (4.89−5.53) 90 4.53 (4.30−4.76) 10–50
V 5.06 (4.75−5.37) 10 4.71 (4.45−4.73) <10
F1 + V 10.27 (9.65−10.89) 50–90 9.24 (8.75 + 9.49) 10
Mouse Oral boost log10 F1 + V IgG1 Predicted protectionb
M4 TG F1–V tom. 9.42 Low
M5 TG F1–V tom. 10.62 High
M6 TG F1–V tom. 10.92 High
M7 TG F1–V tom. 10.62 High
M8 TG F1–V tom. 10.92 High
M9 TG F1–V tom. 9.12 Low
M22 W.T. tomato 9.42 Low
M23 W.T. tomato 9.42 Low
M25 W.T. tomato 8.83 Low
M26 W.T. tomato 9.12 Low
M27 W.T. tomato 9.42 Low
a Numbers in parenthesis are the confidence limits at 95% of the mean. TG: transgenic; W.T: wild type or non-transformed tomato; CFU: colony-formation
units.
b Predictions were based in the study of Williamson et al. [48] that correlated total IgG1 titer to (F1 + V) with protection.
mouse, the predicted protection in four out of six of the mice
boosted with F1–V tomato was high (at least 90%) in clear
contrast with the low protection in the five mice boosted with
control tomato.
In mice boosted with F1–V transgenic tomato, the ratio of
average F1- and V-specific IgG1/IgG2a concentrations was
200 and 117, respectively. This indicates a type 2 T-helper
cell immune response (Th2), which is associated particularly
with a humoral response, the appropriate response to generate
protection against a predominantly extracellular bacterium
like Y. pestis [49].
F1- and V-specific mucosal IgA was elicited only in mice
boosted with oral transgenic F1–V tomato. It was not detected
in mice boosted with control tomato at any time during the
assay or in those mice treated only with subcutaneous bac-
terial F1–V (positive controls). This confirms previous find-
ings that mucosal surfaces are usually poorly protected with
IgA following parenteral administration of vaccines. Mucosal
vaccination offers the added advantage that systemic immu-
nity can be induced in concert with local responses because
of translocation of antigenic material from sub-epithelial
compartments to systemic immunoresponsive tissues such
as spleen [33]. For plague, although mucosal IgA may be
important for protection of the upper respiratory tract, it is
IgG to F1 and V that is protective against an aerosol chal-
lenge [13]. Thus, effective mucosal vaccines for pneumonic
p
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orally immunogenic when produced and delivered in plant
tissues. Plant-expressed F1–V has the potential to be useful
as a booster vaccine against plague since it is able to elicit
specific mucosal sIgA and serum IgG1 responses. A prime-
boost vaccine for plague also has practical implications. In
an imminent or post-release bioterrorism event, the ability to
dispense a parenteral priming dose with the distribution of
tomato powder pills that could be self administered would
greatly improve national preparedness.
In future experiments we will test higher doses of plant-
made F1–V using only green fruit from second or later
generation plants, and will also test the addition of vari-
ous potential oral adjuvants. Increased protein levels might
induce a stronger and more prolonged immune response with-
out the need for previous priming with parenteral F1–V. The
vaccinated mice will be challenged withY. pestis to determine
the degree of protection achieved.
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